101 related articles for article (PubMed ID: 3754086)
1. Phase II trial of piperazinedione in the treatment of advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Homesley HD; Petty W
Am J Clin Oncol; 1986 Feb; 9(1):21-3. PubMed ID: 3754086
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Homesley HD; Hacker N; Curry SL
Am J Clin Oncol; 1985 Oct; 8(5):350-2. PubMed ID: 3840643
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Blessing J; Homesley HD; Adcock LL
Am J Clin Oncol; 1983 Aug; 6(4):423-6. PubMed ID: 6688150
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate in advanced endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group.
Muss HB; Blessing JA; Hatch KD; Soper JT; Webster KD; Kemp GM
Am J Clin Oncol; 1990 Feb; 13(1):61-3. PubMed ID: 2407104
[TBL] [Abstract][Full Text] [Related]
6. Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Homesley HD; Lewis GC
Gynecol Oncol; 1986 Mar; 23(3):358-63. PubMed ID: 3754234
[TBL] [Abstract][Full Text] [Related]
7. Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Fowler WC; Hatch K
Cancer Treat Rep; 1986 Sep; 70(9):1097-100. PubMed ID: 3755650
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Homesley H; Creasman WT; Sutton G
Gynecol Oncol; 1989 Apr; 33(1):68-70. PubMed ID: 2703169
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Lagasse LD; DiSaia PJ; Homesley HD
Am J Clin Oncol; 1984 Jun; 7(3):253-6. PubMed ID: 6539565
[TBL] [Abstract][Full Text] [Related]
10. Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.
Thigpen JT; Blessing JA; Ball H; Hanjani P; Manetta A; Homesley H
Gynecol Oncol; 1988 Nov; 31(3):435-8. PubMed ID: 3141250
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwest Oncology Group Study.
Thigpen JT; Kronmal R; Vogel S; Hynes HE; Nahhas W; Belt RJ; Balcerzak SP; Epstein RB; Costanzi JJ
Am J Clin Oncol; 1987 Oct; 10(5):429-31. PubMed ID: 3661494
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Thigpen JT; Buchsbaum HJ; Mangan C; Blessing JA
Cancer Treat Rep; 1979 Jan; 63(1):21-7. PubMed ID: 369691
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group.
Thigpen JT; Blessing JA; Wilbanks GD
Am J Clin Oncol; 1986 Feb; 9(1):18-20. PubMed ID: 3953489
[TBL] [Abstract][Full Text] [Related]
14. A phase II clinical trial of diaziquone in the treatment of patients with recurrent endometrial carcinoma. A Gynecologic Oncology Group study.
Slayton RE; Blessing JA; DiSaia PJ; Phillips G
Am J Clin Oncol; 1988 Dec; 11(6):612-3. PubMed ID: 3055931
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Homesley HD; Berek JS; Creasman WT
Gynecol Oncol; 1986 Jan; 23(1):101-4. PubMed ID: 3943746
[TBL] [Abstract][Full Text] [Related]
16. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of vincristine in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study.
Broun GO; Blessing JA; Eddy GL; Adelson MD
Am J Clin Oncol; 1993 Feb; 16(1):18-21. PubMed ID: 8424397
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Delgado G
Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059
[No Abstract] [Full Text] [Related]
19. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Beecham J; Homesley H; Yordan E
J Clin Oncol; 1991 Nov; 9(11):1962-6. PubMed ID: 1941054
[TBL] [Abstract][Full Text] [Related]
20. ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study.
Homesley HD; Blessing JA; Conroy J; Hatch K; DiSaia PJ; Twiggs LB
Am J Clin Oncol; 1986 Feb; 9(1):15-7. PubMed ID: 3953488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
